Severe myoclonic epilepsy in infancy: toward an optimal treatment.

Article Details

Citation

Copy to clipboard

Ceulemans B, Boel M, Claes L, Dom L, Willekens H, Thiry P, Lagae L

Severe myoclonic epilepsy in infancy: toward an optimal treatment.

J Child Neurol. 2004 Jul;19(7):516-21.

PubMed ID

15526956 [ View in PubMed

]

Abstract

Severe myoclonic epilepsy in infancy, or Dravet syndrome, is one of the catastrophic epilepsy syndromes. In the past, treatment was mainly based on valproate and phenobarbital. Recently, some of the new antiepilepsy drugs, such as topiramate and stiripentol, have been shown to be promising in the treatment of this epilepsy syndrome. The treatment regimen of 12 children with Dravet syndrome and proven mutations in the alpha subunit of the sodium channel SCN1A is reported here. Five patients on the "traditional" treatment regimen are compared with seven children on an "optimal" treatment regimen based on a combination of valproate and topiramate. With respect to the literature and our own experience, we propose guidelines for "optimal" treatment of children with severe myoclonic epilepsy in infancy. This includes prevention of hyperthermia, rigorous treatment of fever, avoiding stressful situations, maintenance treatment based on a combination of only two antiepilepsy drugs (ie, valproate and topiramate), and a strict acute seizure treatment based on benzodiazepines. To prevent long-lasting periods of status epilepticus, this acute seizure treatment must be taught to parents and caregivers.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Topiramate	Voltage-gated sodium channel alpha subunit (Protein Group)	Protein group	Humans	Yes	Inhibitor	Details